Preferred Label : Enristomig;
NCIt synonyms : Anti-PD-L1/CD137 Bispecific Antibody INBRX-105; PDL1 x CD137 Bispecific Antibody INBRX-105; PDL1 x 4-1BB Bispecific Antibody INBRX-105; Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105;
NCIt definition : A recombinant, humanized, bispecific antibody targeting both the human programmed
death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily
member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic
activities. Upon administration, enristomig simultaneously targets and binds to 4-1BB,
which is expressed on a variety of leukocyte subsets including activated T-lymphocytes,
and PD-L1 expressed on tumor cells. Through 4-1BB binding, enristomig acts as a conditional
4-1BB agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity.
At the same time, Ienristomig prevents PD-L1 from binding to and activating its receptor,
programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell
inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated
tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to
PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells,
suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein
of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor
that plays a key role in T-cell proliferation, survival and cytolytic activity.;
UNII : 3CX9U8V1CV;
CAS number : 2539845-73-1;
Molecule name : INBRX-105; INBRX 105; ES-101; ES 101;
NCI Metathesaurus CUI : CL969077;
Origin ID : C159978;
UMLS CUI : C5854837;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
